In the Spotlight...
Reprogramming CAR with cytokine signaling increases the efficacy of CAR-T cell therapy in solid tumour treatment and confers sustained immune memory
Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases
Immune-remodeling mRNAs expressing IRF8 or NIK generate durable antitumor immunity in multiple cancer models
Differential assembly of mouse and human tumor microenvironments
Previous Digests
Yin and Yang of tumoral NK cells: cytotoxic and suppressive phenotypes uncovered
May 19, 2026
NK cells are promising targets for cancer immunotherapy, but clinical results have so far been limited. Therefore, there is a need to better understand NK cell subphenotypes and their function in tumors. Two recent papers characterized tumoral NK cells...
Intratumoral anti-CTLA-4 could reduce severe AEs: Results from a phase 1b clinical trial
May 13, 2026
The combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), both administered intravenously, has been approved for the treatment of cancer in a variety of settings since 2015, but its use is frequently hindered by severe adverse events, more often associated...
NK cells unleashed by Treg ablation
May 6, 2026
When tumors lose expression of MHC-I under the selective pressure of CD8+ T cells, NK cells may step in and take on a more prominent antitumor role, but often this is still insufficient to control tumors. Investigating potential mechanisms...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
